New pill shows promise for controlling blood pressure in rare hormone disorder

NCT ID NCT04605549

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new drug called CIN-107 in 15 adults with primary aldosteronism, a condition where the body makes too much of a hormone that raises blood pressure. Participants took the drug once daily for up to 12 weeks to see if it safely lowered blood pressure. The goal was to find a better way to manage this condition.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: CIN-107 (a drug taken as a tablet once daily)
What this could lead to: If it works, this could provide a new treatment option for people with primary aldosteronism to better control their blood pressure.
What could go wrong: This was a small, early-phase study with only 15 participants, so results may not apply to everyone. The drug may cause side effects or not work as well in larger, longer trials.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPERALDOSTERONISM are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hyperaldosteronism primary aldosteronism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERALDOSTERONISM PRIMARY ALDOSTERONISM

Contacts and locations

Locations

Research Site

Greenbrae, California, 94904, United States
Research Site

San Francisco, California, 94110, United States
Research Site

West Hollywood, California, 90048, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Baltimore, Maryland, 21287, United States
Research Site

Ann Arbor, Michigan, 48109, United States
Research Site

Rochester, Minnesota, 55905, United States
Research Site

Cincinnati, Ohio, 45245, United States
Research Site

Columbus, Ohio, 43210, United States
Research Site

Dallas, Texas, 75390-9047, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.